Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.720
-0.020 (-1.15%)
At close: Dec 26, 2025, 4:00 PM EST
1.690
-0.030 (-1.74%)
After-hours: Dec 26, 2025, 4:36 PM EST
Entera Bio Employees
As of December 31, 2024, Entera Bio had 20 total employees, including 18 full-time and 2 part-time employees. The number of employees increased by 2 or 11.11% compared to the previous year.
Employees
20
Change (1Y)
2
Growth (1Y)
11.11%
Revenue / Employee
$6,200
Profits / Employee
-$539,050
Market Cap
78.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20 | 2 | 11.11% |
| Dec 31, 2023 | 18 | 1 | 5.88% |
| Dec 31, 2022 | 17 | -3 | -15.00% |
| Dec 31, 2021 | 20 | 2 | 11.11% |
| Dec 31, 2020 | 18 | -6 | -25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENTX News
- 3 days ago - Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - GlobeNewsWire
- 4 days ago - Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - GlobeNewsWire
- 5 weeks ago - Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewsWire
- 2 months ago - Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - GlobeNewsWire
- 2 months ago - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - GlobeNewsWire
- 5 months ago - Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis - GlobeNewsWire
- 8 months ago - Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire